SAFETY AND EFFICACY OF INSULIN ANALOG NOVOMIX30 IN IRANIAN PATIENTS WITH TYPE 2 DIABETES: RESULTS OF THE A1CHIEVE STUDY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

KHAMSEH MOHAMMAD EBRAHIM; ESTEGHAMATI ALIREZA; PISHDAD GHOLAMREZA; NIAFAR MITRA; TAGHAVI MORTEZA; RASHIDI HOMEIRA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Payesh Year:2014 | Volume:13 | Issue:6 Page(s): 695-703

Download Full-Text

Persian Verion

View:

1,689

Download:

Cites:

Information Journal Paper

Title

SAFETY AND EFFICACY OF INSULIN ANALOG NOVOMIX30 IN IRANIAN PATIENTS WITH TYPE 2 DIABETES: RESULTS OF THE A1CHIEVE STUDY

Author(s)

Keywords

DIABETES MELLITUSQ3

TYPE 2Q2

CHRONIC COMPLICATIONSQ2

METABOLIC CONTROLQ2

Abstract

Objective: The aim of this study was to assess the safety and efficacy of treatment with insulin analog Novomix30 in Iranian patients with TYPE 2 diabetes using the results of the A1chieve study.Methods: The A1chieve study was a 24 week, open-label, multicenter, observational study of people with TYPE 2 diabetes. The study was conducted in 28 countries across four continents on 66, 726 people with TYPE 2 diabetes, both insulin users and noninsulin users, to assess the safety and efficacy of Novomix30. This article reports the results of 919 Iranian patients with TYPE 2 diabetes treated with insulin Novomix30.Results: After 24 weeks treatment with Novomix30, HbA1c reduced significantly (P<0.001). Despite a significant reduction in fasting blood sugar and postprandial sugars, the incidence of severe and nocturnal hypoglycemia was significantly decreased in prior insulin users. The mean arterial blood pressure decreased significantly and the quality of life improved in all patients.Conclusion: Insulin Novomix30 was well tolerated despite good glycemic control and the incidence of hypoglycemia was not increased in Iranian patients with TYPE 2 diabetes.

Cites

No record.

References

Cite

APA: Copy

KHAMSEH, MOHAMMAD EBRAHIM, ESTEGHAMATI, ALIREZA, PISHDAD, GHOLAMREZA, NIAFAR, MITRA, TAGHAVI, MORTEZA, & RASHIDI, HOMEIRA. (2014). SAFETY AND EFFICACY OF INSULIN ANALOG NOVOMIX30 IN IRANIAN PATIENTS WITH TYPE 2 DIABETES: RESULTS OF THE A1CHIEVE STUDY. PAYESH, 13(6), 695-703. SID. https://sid.ir/paper/23977/en

Vancouver: Copy

KHAMSEH MOHAMMAD EBRAHIM, ESTEGHAMATI ALIREZA, PISHDAD GHOLAMREZA, NIAFAR MITRA, TAGHAVI MORTEZA, RASHIDI HOMEIRA. SAFETY AND EFFICACY OF INSULIN ANALOG NOVOMIX30 IN IRANIAN PATIENTS WITH TYPE 2 DIABETES: RESULTS OF THE A1CHIEVE STUDY. PAYESH[Internet]. 2014;13(6):695-703. Available from: https://sid.ir/paper/23977/en

IEEE: Copy

MOHAMMAD EBRAHIM KHAMSEH, ALIREZA ESTEGHAMATI, GHOLAMREZA PISHDAD, MITRA NIAFAR, MORTEZA TAGHAVI, and HOMEIRA RASHIDI, “SAFETY AND EFFICACY OF INSULIN ANALOG NOVOMIX30 IN IRANIAN PATIENTS WITH TYPE 2 DIABETES: RESULTS OF THE A1CHIEVE STUDY,” PAYESH, vol. 13, no. 6, pp. 695–703, 2014, [Online]. Available: https://sid.ir/paper/23977/en

Related Journal Papers